TY - JOUR
T1 - Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy
AU - Loeb, Stacy
AU - Roehl, Kimberly A.
AU - Viprakasit, Davis P.
AU - Catalona, William J.
N1 - Funding Information:
Acknowledgment Statement : This study was supported by the Urological Research Foundation.
PY - 2008/7
Y1 - 2008/7
N2 - Background: Randomized trials have shown an improvement in progression-free survival rates with adjuvant radiation therapy (ART) after radical prostatectomy for patients with a high risk of cancer recurrence. Less is known about the relative advantages and disadvantages of initial observation with delayed salvage radiation therapy (SRT). Objective: To examine the results of SRT in a large single-surgeon radical prostatectomy series. Design, Setting, and Participants: From a radical prostatectomy database, we identified 859 men with positive surgical margins (SM+), extracapsular tumor extension (ECE), or seminal vesicle invasion (SVI) who chose to defer ART. Following a period of initial observation, 192 ultimately received SRT for prostate-specific antigen (PSA) progression. Measurements: Survival analysis was performed to examine the outcomes of initial observation followed by SRT. Results and Limitations: In patients with SM+/ECE and SVI, the 7-yr PSA progression-free survival rates with observation were 62% and 32%, respectively. Among those who had PSA progression, 56% and 26%, respectively, maintained an undetectable PSA for 5 yr after SRT. The long-term rates of undetectable PSA associated with an SRT strategy were 83% and 50% for men with SM+/ECE and SVI, respectively. In the subset of 716 men who did not receive any hormonal therapy, the corresponding long-term rates of undetectable PSA were 91% and 75%, respectively. Conclusions: Following radical prostatectomy, initial observation followed by delayed SRT at the time of PSA recurrence is an effective strategy for selected patients with SM+/ECE. Some patients with SVI may also benefit from this strategy. However, additional prospective studies are necessary to further examine the survival outcomes following SRT.
AB - Background: Randomized trials have shown an improvement in progression-free survival rates with adjuvant radiation therapy (ART) after radical prostatectomy for patients with a high risk of cancer recurrence. Less is known about the relative advantages and disadvantages of initial observation with delayed salvage radiation therapy (SRT). Objective: To examine the results of SRT in a large single-surgeon radical prostatectomy series. Design, Setting, and Participants: From a radical prostatectomy database, we identified 859 men with positive surgical margins (SM+), extracapsular tumor extension (ECE), or seminal vesicle invasion (SVI) who chose to defer ART. Following a period of initial observation, 192 ultimately received SRT for prostate-specific antigen (PSA) progression. Measurements: Survival analysis was performed to examine the outcomes of initial observation followed by SRT. Results and Limitations: In patients with SM+/ECE and SVI, the 7-yr PSA progression-free survival rates with observation were 62% and 32%, respectively. Among those who had PSA progression, 56% and 26%, respectively, maintained an undetectable PSA for 5 yr after SRT. The long-term rates of undetectable PSA associated with an SRT strategy were 83% and 50% for men with SM+/ECE and SVI, respectively. In the subset of 716 men who did not receive any hormonal therapy, the corresponding long-term rates of undetectable PSA were 91% and 75%, respectively. Conclusions: Following radical prostatectomy, initial observation followed by delayed SRT at the time of PSA recurrence is an effective strategy for selected patients with SM+/ECE. Some patients with SVI may also benefit from this strategy. However, additional prospective studies are necessary to further examine the survival outcomes following SRT.
KW - Adjuvant radiation
KW - Progression
KW - Prostate cancer
KW - Radical prostatectomy
KW - Salvage radiation
UR - http://www.scopus.com/inward/record.url?scp=44149099743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44149099743&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2008.03.066
DO - 10.1016/j.eururo.2008.03.066
M3 - Article
C2 - 18400368
AN - SCOPUS:44149099743
SN - 0302-2838
VL - 54
SP - 88
EP - 96
JO - European urology
JF - European urology
IS - 1
ER -